ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Outlines Need For $3,873 Billion To Seize Cancer Research Opportunities

October 30, 1998

DCT Issues New Program Announcement On Clinical Research

December 5, 1980

FDA Advisors Recommend Approval Of Leucovorin, Hexamethylmelamine

June 16, 1989

Reinventing NCI: clinical Trials report Calls for Study Section, increased Funding For Cooperative Groups

October 3, 1997

Public Health Service: Blumenthal Declines White House Job

November 14, 1997

Bypass Budget For FY 1992 Shown In Chart

May 18, 1990